Vycellix, Inc., an immuno-centric discovery life science company with a focus on natural killer cell-based (NK cell) therapeutics, today announced that members of its executive leadership team are scheduled to present and moderate panel sessions at the following upcoming life science conferences this week.
Our News
We’re on a mission to start a conversation with your customers in this fast connected world.
TAMPA, FLORIDA & DUBLIN, IRELAND – March 25, 2020 – Vycellix™, Inc., an immuno-discovery cell & gene therapy company, and Avectas Limited, a cell engineering technology business, today jointly announced that the companies have entered into a collaboration agreement to develop proprietary approaches for cell-based immunotherapeutic products.